Health state utilities for non small cell lung cancer
Top Cited Papers
Open Access
- 1 January 2008
- journal article
- research article
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 6 (1) , 84
- https://doi.org/10.1186/1477-7525-6-84
Abstract
Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash and hair loss.Keywords
This publication has 23 references indexed in Scilit:
- Health state utilities for metastatic breast cancerBritish Journal of Cancer, 2006
- Assessment of Quality of Life in the Supportive Care Setting of the Big Lung Trial in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Symptom prevalence, distress, and change over time in adults receiving treatment for lung cancerPsycho‐Oncology, 2003
- Dying from cancer in developed and developing countries: lessons from two qualitative interview studies of patients and their carersBMJ, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer*Chest, 2003
- Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the communityBMJ, 2002
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- A New Decision Model for Cost-Utility Comparisons of Chemotherapy in Recurrent Metastatic Breast CancerPharmacoEconomics, 1996